Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States Cost-Effectiveness of HCV Treatment With Sofosbuvir and Ledipasvir -

Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States Cost-Effectiveness of HCV Treatment With Sofosbuvir and Ledipasvir
Information type: Other primary research
Source: Annals of Internal Medicine
Specialities: Liver disorders
Summary
This report, based on a microsimulation model of the natural history of HCV infection concludes that treating eligible HCV-infected persons in the US with sofosbuvir and lefispavir would cost an additional $65b in the next 5 years, whereas the cost offsets would be $16b.
UKMi comment
In DRAFT guidance, NICE has recommended ledipasvir-sofosbuvir (Harvoni) as a treatment option for some adults with genotype 1 or 4 chronic hepatitis C. Consultation on this draft guidance closes on 23 March 2015.
Related links: DRAFT NICE guidance